Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.64 |
| ▸ | ACHE | P22303 | 13/20 | 0.64 |
| ▸ | BCHE | P06276 | 12/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761943 | 1.00 | BACE1 (0.64) | BACE1ACHEBCHEDRD2DRD4 | |
| SCHEMBL8259147 | 1.00 | BACE1 (0.64) | BACE1ACHEBCHEDRD2DRD4 | |
| SCHEMBL13761638 | 0.91 | ALDH1A1 (0.60) | BACE1ACHEBCHEALDH1A1 | |
| SCHEMBL3307906 | 0.91 | ACHE (0.62) | BACE1ACHEBCHEALDH1A1MEN1 | |
| SCHEMBL21569736 | 0.87 | ACHE (0.50) | BACE1ACHEBCHEALDH1A1 | |
| SCHEMBL12844707 | 0.87 | BACE1 (0.59) | BACE1ACHEBCHEDRD2DRD4 | |
| SCHEMBL242760 | 0.83 | ACHE (0.69) | BACE1ACHEBCHEDRD2DRD4 | |
| SCHEMBL724604 | 0.83 | ACHE (0.69) | BACE1ACHEBCHEDRD2DRD4 | |
| SCHEMBL242759 | 0.83 | ACHE (0.69) | BACE1ACHEBCHEDRD2DRD4 | |
| Bromide SCHEMBL2497824 | 0.81 | ACHE (0.68) | BACE1ACHEBCHEDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025036241-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING | RIBOPEUTIC INC. (CN) | 2025-02-20 | — | — | WO | disclosed |
| CN-118786117-A | Heterocyclic amides and methods of use thereof | 亚根达医疗公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-112203653-B | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023092098-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-7982033-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7928135-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7906529-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2213673-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-20100081662-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081662-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | BACE1 2963/4885ACHE 4529/4885BCHE 4270/4885 |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE1, WEE2, CCNE1 | BACE1 4676/4885ACHE 4776/4885BCHE 4449/4885 |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | BACE1 3641/4885ACHE 4341/4885BCHE 4772/4885 |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | BACE1 1574/4885ACHE 4264/4885BCHE 2627/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | BACE1 516/4885ACHE 110/4885BCHE 223/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | BACE1 3641/4885ACHE 4341/4885BCHE 4772/4885 |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | BACE1 2889/4885ACHE 1346/4885BCHE 3613/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | BACE1 516/4885ACHE 110/4885BCHE 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.